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Abstract
Lymph node involvement is a major prognostic variable in breast cancer. Whether the molecular mechanisms that
drive breast cancer cells to colonize lymph nodes are shared with their capacity to form distant metastases is yet to
be established. In a transcriptomic survey aimed at identifying molecular factors associated with lymph node
involvement of ductal breast cancer, we found that luminal differentiation, assessed by the expression of estrogen
receptor (ER) and/or progesterone receptor (PR) and GATA3, was only infrequently lost in node-positive primary
tumors and in matched lymph node metastases. The transcription factor GATA3 critically determines luminal lineage
specification of mammary epithelium and is widely considered a tumor and metastasis suppressor in breast cancer.
Strong expression of GATA3 and ER in a majority of primary node-positive ductal breast cancer was corroborated by
quantitative RT-PCR and immunohistochemistry in the initial sample set, and by immunohistochemistry in an
additional set from 167 patients diagnosed of node-negative and –positive primary infiltrating ductal breast cancer,
including 102 samples from loco-regional lymph node metastases matched to their primary tumors, as well as 37
distant metastases. These observations suggest that loss of luminal differentiation is not a major factor driving the
ability of breast cancer cells to colonize regional lymph nodes.
Citation: Calvo J, Sánchez-Cid L, Muñoz M, Lozano JJ, Thomson TM, et al. (2013) Infrequent Loss of Luminal Differentiation in Ductal Breast Cancer
Metastasis. PLoS ONE 8(10): e78097. doi:10.1371/journal.pone.0078097
Editor: William B. Coleman, University of North Carolina School of Medicine, United States of America
Received June 28, 2013; Accepted September 7, 2013; Published October 21, 2013
Copyright: © 2013 Calvo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JC and LS were supported by grants from the Institut d’Investigacions Biomèdiques August Pi y Sunyer. This study was supported by grants
from the Xarxa de Bancs de Tumours de Catalunya-Pla Director d’Oncologia and Fondo Europeo de Desarrollo Regional, Unión Europea “Una manera de
hacer Europa”, Red de Biobancos RETIC RD06/0020 and Red Temática de Investigación Cooperativa del Cáncer (RD06/0020/0039,RD12/0036/0023)
from The National Institute of Health Carlos III, grant SAF2012-40017-C02-02 (Ministry of Economy and Competitivity) and grant FIS-PI080274 (Ministry of
Science and Innovation) to PLF; and grants SAF2008-04136-C02-01 and SAF2011-24686 (Ministry of Science and Innovation), SAF2012-40017-C02-01
(Ministry of Economy and Competitivity), AECC of Barcelona and 2009SGR1482 (Agència de Gestió d’Ajuts Universitaris i de Recerca de la Generalitat de
Catalunya) to TMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: plfernan@clinic.ub.es (PLF); titbmc@ibmb.csic.es (TMT)
Introduction
Morphological and molecular subtypes of breast cancer have
been associated with distinct stages of normal epithelial
differentiation [1]. The most common morphological types of
breast cancer are ductal and lobular infiltrating carcinomas [2].
Intrinsic molecular classifications based on transcriptomic
analysis provide additional knowledge as to the biological basis
of breast cancer heterogeneity and the corresponding putative
cells of origin. Based on specific sets of markers, the four major
molecular types of breast cancer are luminal A, luminal B,
basal and HER2-enriched [3,4]. Molecular classifications of
breast cancer can afford prognostic indicators independent of
morphological assessment [5-7]. However, morphological
diagnosis of breast cancer subtypes maintains a prevalent use
in many clinical settings mostly because of considerations of
cost effectiveness and prompt diagnosis and classification.
Furthermore, when combined with selected molecular markers,
including the immunohistochemical detection of hormone
receptors, HER2 and the proliferation marker Ki67 and copy
number quantification of the HER2 locus by FISH, it provides
adequate information for the therapeutic management of the
tumors, as well as reasonable prognostic value, probably not
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inferior to molecular classifications for the most common types
of breast cancer [8-11].
In addition to molecular and morphological classifications,
histological grade is a prognostic indicator [12,13], That breast
cancer histological grades have a biological basis is supported
by the strong molecular correlates associated with each
discrete grade [14], suggesting that expert application of
appropriate morphological criteria can extract biologically and
clinically relevant information. In molecular terms, less
differentiated luminal breast cancers, and thus higher
histological grade tumors, are expected to express lower levels
of luminal lineage differentiation markers, including estrogen
receptor and GATA3.
A third major prognostic variable in breast cancer is lymph
node involvement at the time of diagnosis and/or first surgery
[12,15,16], usually appraised along with tumor size, although
these two parameters may not be necessarily linked
mechanistically [17]. Lymph node involvement and tumor size
provide prognostic information independent of molecular or
morphological classifications [18]. Despite the prognostic
importance of lymph node involvement, comparatively little is
known about the molecular mechanisms that endow breast
cancer cells with the capacity to metastasize to regional lymph
nodes [19], as opposed to molecules identified as involved in
breast cancer distant organ colonization [20]. Also, whether
lymph node metastasis and distant organ metastasis reflect
common or differentiated biological properties of tumor cells is
disputed [19,21], with evidences for and against lymph node
involvement reflecting general metastatic potentials of breast
cancer cells or representing a step that precedes distant organ
dissemination in linear models of breast cancer evolution [22].
We report here that the expression of the breast luminal
differentiation markers estrogen receptor and GATA3 in
metastatic ductal breast cancers with a luminal phenotype is
not generally lost or decreased upon regional or distant
metastasis. Our observations suggest that loss of luminal
differentiation is not a frequent process associated with the
ability of luminal breast cancer cells to colonize regional lymph
nodes or distant metastatic sites.
Materials and Methods
Ethics Statement
Patient selection and sample procurement complied with
Spanish laws regarding data protection and written informed
consent, which was obtained from all patients and stored at the
Hospital Clinic Biobank, and were approved by the Hospital
Clinic and IDIBAPS Ethics Committee and Review Board.
Sample procurement and selection
For transcriptomic analysis, we selected untreated grade 2 or
3 infiltrating ductal carcinoma cases, 7 primary tumors without
axillary lymph node involvement at presentation (primary, non-
metastatic, PNM), 18 primary tumors with at least one affected
axillary lymph node (primary, metastatic, PM), and their
matching tumor-infiltrated lymph nodes (LNM). Samples were
embedded in OCT compound (Sakura Finetec, Zoeterwoude,
Nederland), snap-frozen in isopentane and stored at - 80 °C
until use. Only samples with at least 70% tumoral epithelium
versus stroma ratios were selected for the study. Three non-
metastatic (normal) axillary lymph nodes(LN(-)) from three of
the above tumors with metastases in other nodes were also
included as controls.
For immunohistochemical analysis, tissue microarrays (TMA)
were built from paraffin-embedded samples, bearing 3-µm
thick, 1-mm diameter duplicate or triplicate cores for each of 52
samples from node-negative primary tumors, 115 node-positive
primary tumors, 111 lymph node metastases, 36 from distant
metastases (16 lung, 5 pleura, 3 liver, 2 brain, peritoneum and
skin, and one from adrenal gland, cerebellum, meninx, muscle,
ovary and trachea), 7 ductal carcinoma in situ (DCIS) and 11
normal breast samples corresponding to normal epithelium
from cases of primary tumors. All primary tumors were of ductal
type and 11 were histological grade 1, 111 grade 2 and 45
grade 3. Primary tumors were classified according to the
expression of luminal markers and HER2 (Table S1). Cases
from the initial molecular analysis were also included in
immunohistochemical analysis.
RNA extraction and microarray analysis
Total RNA was extracted from 20-30 µm cryosections with
the RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by
DNAse treatment, and quality and concentration were
assessed with the 2100 Agilent Bioanalyzer (Agilent
Technologies, Santa Clara, CA). Total RNA was
retrotranscribed to cDNA, transcribed to cRNA, labeled with
biotin and hybridized to Human Genome U133 A2.0 Arrays
(Affymetrix, Santa Clara, CA). Microarray data were normalized
using the robust multi-array (RMA) algorithm [23]. Next, those
probes with a maximum expression value lower than 5 were
eliminated. Significance Analysis of Microarrays (SAM-R) [24]
was applied to identify differentially expressed genes, selecting
those genes with a False Discovery Rate (FDR) < 10%. Gene
co-regulation was determined as the strength of the association
between two gene expression profiles, for which Pearson
correlation indexes (r) were computed between a preselected
probelist versus the rest of filtered probes, using the cor.test
function from the R-package. Microarray data are available at
GEO accession GSE44408.
Real-time RT-PCR (qPCR)
Reverse transcription was performed from total RNA using
the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems, Carlsbad, CA), and transcript levels determined by
means of Taqman Low Density Arrays (Applied Biosystems) on
an ABI Prism 7900HT instrument (Applied Biosystems).
Epithelial tumor cells were purified in selected cases by laser-
microdissection (P.A.L.M. Mikrolaser, Bernried, Germany). A
minimum of 2 mm2 of epithelium was obtained per sample,
from which total mRNA was extracted using the RNeasy Micro
Kit (Qiagen). Relative transcript quantification was determined
by the ΔΔCt method using RPN18 transcripts as a reference
and data were analyzed using the SDS 2.3 software (Applied
Biosystems). ΔCt data were used to build hierarchical clusters
by UPGMA (Unweighted Pair Group Method with Arithmetic
Differentiation in Breast Cancer Metastasis
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Mean) [25]. The TaqMan assays used are detailed in Table S2
of File S1.
Immunohistochemical analysis
Samples were deparaffinized and rehydrated prior to antigen
retrieval, followed by incubation with primary antibodies (Table
S3 of File S1), incubation with polymer-peroxidase-conjugated
secondary antibody and developed with diaminobenzidine.
Slides were counterstained with haematoxylin, dehydrated and
coverslipped. This process was performed in an automatic
immunostainer (Bond Automated Immunohistochemistry & In-
Situ Hybridisation System). The reaction specificity was
ascertained by the absence of staining when using a non-
specific isotype-matched primary antibody.
Nuclear immunostaining for ERα, PR and GATA3 was
evaluated according to intensity (I; 0, 1, 2 and 3) and
percentages of positive cells with the following discrete
intervals (P): 0, 1 (1 - 9%), 2 (10 - 49%), 3 (50 - 74%) and 4 (75
- 100%). The final staining histoscore (Hscore) was obtained by
multiplying intensity and percentage interval values (Hscore = I
x P), thus ranging from 0 to 12. Hscores ≥ 2 were considered
as positive staining. Membrane staining for HER2 was
assessed following recommendations of the American College
of Pathologists [26] as 0, 1, 2 and 3. Only cases with HER2
score equal to 3 were considered HER2(+). Primary tumors
were classified according to the expression of hormone
receptors and HER2. Cases were considered “luminal” with
positive ER and/or PR (≥ 10% positive cells; ≥ 2 in our discrete
scoring system) and negative HER2 (≤ 2); HER2(+) for cases
with a immunohistochemical HER2 score of 3, irrespective of
ER or PR; and “triple negative” (TN) when the three markers
were negative.
Statistical analysis
Data were analyzed using the SPSS package version 13.0
(SPSS Inc., Chicago, IL). Kruskal-Wallis test was applied in
comparisons of means among groups, Mann-Whitney test for
two-group comparisons and Chi square and Fisher’s exact test
when analyzing categories. Differences were considered
significant when P ≤ 0.05. Kaplan-Meyer curves and log-rank
tests were used to assess metastasis-free survival (MFS),
defined as the time elapsed from diagnosis to detection of
distant metastases.
Results
Expression profiling of node-positive vs. node-negative
ductal breast cancers
Although lymph node metastasis is a major prognostic factor
in breast cancer, little is known about the molecular
mechanisms that confer breast cancer cells the capacity to
metastasize to regional lymph nodes. To study this process, we
compared the transcriptional profiles of 18 node-positive
primary tumors, along with their lymph node metastatic
samples, with 7 primary tumors with no detectable lymph node
involvement at surgery.
Unsupervised analysis of the microarray data failed to yield a
clear-cut separation between the three classes of samples,
namely primary node-negative (PNM), primary node-positive
(PM) and lymph node metastases (LNM). In fact, node-positive
primary tumors tended to pair with their matched lymph node
metastases rather than form clusters with other node-positive
primary tumors (Figure 1A), suggesting that there are no major
differences in global gene expression patterns between node-
positive and node-negative primary ductal breast cancer. A
supervised approach was taken in an attempt to identify
specific groups of transcripts whose levels distinguish these
classes of samples. At a significance level of P ≤ 0.05 and fold
changes in log2 of expression values ranging between 2.5 and
-2.5, 107 genes were expressed at higher levels and 16 at
lower levels in PNM vs. PM (Figure 1B). Many of the genes
expressed at significantly higher levels in lymph node
metastases than in primary tumors correspond to lymphoid
and/or myeloid differentiation genes, suggesting that they
merely reflect partial contamination of these samples with
hematopoietic cells.
Of the genes differentially expressed between node-positive
and node-negative primary tumors, 61 were further analyzed
by qPCR in 5 PNM and 5 PM tumors as well as 5 LNM, in
order to confirm their differential expression. These genes were
selected according to their capacity to discriminate between
groups of samples (node-positive vs. node-negative primary
tumors and primary vs. metastatic samples). Additional genes
were also analyzed based on their established or proposed
roles in breast cancer metastatic progression. All but one PNM
samples were segregated from PM indicating that these genes
can distinguish node-negative from node-positive primary
tumors (Figure 2A). Additionally, the expression levels for the
same 61 genes were also quantified in laser-microdissected
epithelial-specific samples from 4 non-tumoral (normal
morphology epithelium), 6 DCIS, 5 PNM tumors, 5 PM tumors
and 5 LNM samples. As with total non-microdissected tissues,
the quantification of the 61 transcripts in microdissected
samples was capable of relatively good discrimination between
node-negative and node-positive samples (Figure 2B). Normal
samples and two DCIS samples clustered together with node-
negative primary tumors, whereas lymph node metastases
clustered together with primary node-positive tumors and the
rest of the DCIS samples. The latter result corroborated that
node-positive primary tumors and their matched lymph node
metastases display highly overlapping transcriptional
repertoires.
Infrequent loss of GATA3 and ER expression in node-
positive ductal breast cancers and metastases
Our comparative transcriptomic analysis yielded relatively
few differentially expressed transcripts between node-positive
and node-negative ductal breast tumors, which precluded
significant inferences of associated signaling pathways or gene
networks. Nevertheless, we noted that the luminal
differentiation factor GATA3 was expressed at relatively high
levels both in PM and in PNM samples, as well as in matched
lymph node metastases (Figures 1 and 2). The levels of other
transcripts associated with breast luminal epithelial
Differentiation in Breast Cancer Metastasis
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differentiation, including ER, FOXA1 and XBP [27-31], followed
a similar pattern, frequently with higher levels in node-positive
than in node-negative primary tumors, and maintenance of
levels in lymph node metastases (Figure 2). Analysis of
transcript co-regulation in our samples showed that additional
genes are expressed in parallel with GATA3, including those
coding for carbonic anhydrase XII (CA12), cyclin D1 (CCND1)
or hepsin (HPN) (Table S4 of File S1), all of which have been
associated with breast cancer [32-35].
The observed increase or maintenance in the expression
levels of GATA3 along with metastatic progression in ductal
breast cancer was unexpected, because this transcription
factor is widely considered a metastasis and tumor suppressor
by virtue of its function as a promoter of the commitment of
Figure 1.  Identification by microarray analysis of genes differentially expressed between node-positive, node-negative and
lymph node metastatic breast cancer samples.  (A) Unsupervised analysis of microarray expression data for node-negative
primary tumors (PNM), node-positive primary tumors (PM) and regional lymph node metastases matched to their primary tumors
(LNM). (B) Supervised analysis showing genes differentially expressed between types of samples.
doi: 10.1371/journal.pone.0078097.g001
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Figure 2.  Expression levels of selected genes that discriminate between node-positive and node-negative breast cancer
samples.  (A) Hierarchical clustering based on QRT-PCR values for 61 genes in whole tissue samples. All but one PNM tumors
were correctly segregated from PM tumors. (B) Hierarchical clustering based on QRT-PCR values for 61 genes in microdissected
samples. Ductal carcinoma in situ (DCIS) samples were analyzed in addition to the sample categories shown in (A). Both analyses
show that, among other genes, GATA3 is intensely expressed both in primary tumors and LNM samples.
doi: 10.1371/journal.pone.0078097.g002
Differentiation in Breast Cancer Metastasis
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progenitor breast epithelial cells to a differentiated luminal
phenotype [36-40]. We thus extended our analysis to examine
the expression of GATA3 and ER by immunohistochemistry in
a larger set of formalin-fixed paraffin-embedded tissue
samples. The examined tumors were stratified according to
their ER, PR and HER2 status as luminal (ER and/or PR
positive, HER2 negative), HER2 (HER2 positive) or triple
negative (ER, PR and HER2 negative) (Table S1).
We observed a predominantly nuclear staining for GATA3 in
luminal cells of normal breast tissue (Figure 3A) [41], generally
with a stronger intensity in malignant tissues than in normal
tissues in matched (Figure 3A-C) and unmatched samples
(Figure 3A, D-F) (Table S1). In cases with a luminal phenotype,
we observed that the frequency of ER or GATA3 positive
samples showed little variation between PMN, PM or LNM,
independent of the histological grade of the primary tumor
(Figure 4). About 80% of HER2(-) distant metastases
expressed ER, GATA3 or both (Figure 4). In HER2(+) cases,
the proportion of ER(-) samples was higher than in luminal
cases, reaching to nearly 50% of PM and their matched LNM
samples (Figure S1 of File S1). However, the proportion of
GATA3(-) samples was similar to that of luminal cases, about
15% in HER2-positive PM and their matched LNM samples
(Figure S1 of File S1). This suggests an uncoupling of the
expression of these two luminal markers in these cases. In
triple-negative cases, all PNM tumors were also GATA3(-)
(Table S1), as expected from their presumed basal-like
phenotype [42]. However, 4 of the 12 triple-negative PM tumors
were GATA3(+), and this positivity was maintained in their
matched lymph node metastases, again suggesting that
expression of GATA3 can occur independently of ER and PR,
in agreement with other reports [43].
These results suggest that loss of luminal differentiation, as
determined by loss or decline of ER and/or GATA3 expression,
is infrequent in luminal-phenotype ductal breast cancer,
irrespective of regional lymph node status and histological
grade. To better assess the expression levels of ER and
GATA3 along the metastatic progression of these tumors, we
determined the Hscores for these markers in matched node-
positive primary tumors (PM) and their corresponding lymph
node metastases (LNM). In tumors with a luminal phenotype,
we observed a decline in ER or GATA3 Hscores in about 30%
of the LNM samples when compared to their matched PM
(Figure 5). The remaining 70% of the samples had equal or
higher Hscores in LNM samples compared to their matched
PM samples. Of further interest, although the expression of
GATA3 and ER was generally concordant between primary
tumors and their matched lymph node metastases, 3 of the
luminal-phenotype PM cases switched from GATA3(-) in PM to
GATA3(+) in their matched lymph node samples, and 3 of the
GATA(+) luminal PM cases became GATA3(-) in their matched
LNM. Similarly, 3 cases in this group switched from ER(-) in
PM to ER(+) in their matched LNM, and 3 other ER(+) cases
switched to ER(-) in their matched LNM (Table S1). These
switches in GATA3 expression between PM and LNM were not
necessarily concordant with the switches in ER expression.
This further highlights that the expression of GATA3 can
uncouple from ER in metastatic transitions.
Our observations corroborate that metastasis to local and
regional lymph nodes of luminal-type breast cancer only
infrequently involves a decline in the expression of ER or
GATA3. As expected, actuarial survival curves showed that
node-positive luminal cases (PM) developed distant
metastases at significantly earlier times than node-negative
cases (Figure 6a). Although relatively few cases with a luminal
primary tumor phenotype were GATA3(-), which precluded
reaching statistical significance, these cases also tended to
present worse distant metastasis-free survival than GATA3(+)
cases (Figure 6b), in agreement with previous work [38,44-46].
Also as expected, triple-negative cases had a worse distant
metastasis-free survival than luminal tumors (Figure 6c).
Discussion
Although primary breast tumors are often successfully
treated, the emergence of metastases is often life-threatening.
As in other carcinomas, the dissemination of cells from the
primary tumor is first detected in regional lymph nodes, the
involvement of axillary lymph nodes being a major prognostic
factor in breast cancer [15,17,19]. In order to acquire a better
insight into the process of lymph node metastasis in ductal
breast cancer, we conducted a microarray-based
transcriptomic survey, followed by real-time PCR quantification
of selected transcripts and immunohistochemical analysis on a
larger panel of samples. Our analysis leads us to propose that
luminal differentiation, as assessed by estrogen receptor and
GATA3 expression levels, is only infrequently lost during the
process of regional lymph node colonization by breast cancer
cells. Alternatively, transient downregulation of the luminal
gene program might take place at the primary tumor site in
association with local invasion and intravasation, followed by
re-expression of the differentiation program after tumor cells
colonize lymph nodes or distant organs. In either case, our
results suggest that, in general, metastatic luminal-phenotype
tumors are not characterized by a stable loss of their
differentiated features. More specifically, loss of GATA3
expression does not appear to be a requirement for the
establishment of metastatic growth in a majority of luminal
breast cancers.
Even though it is not recognized as a “canonical” hallmark of
cancer [47], loss of differentiation constitutes a distinctive
feature of many tumors and an indicator of malignant
progression [48] and the basis for therapies aimed at restoring
differentiated properties of tumor cells [49,50]. The discovery
that loss of GATA3, a critical factor for luminal lineage
determination during breast epithelial differentiation [36,39],
can drive tumorigenesis in experimental models [37,38] and
correlates with poor prognosis in breast cancer patients
[40,45,46,51] justifiably prompted its consideration as a tumor
suppressor, as well as expectations that new therapeutic
strategies could be devised to induce differentiated features in
breast cancer cells [52].
In agreement with its function as a determinant of breast
epithelium luminal differentiation, we observed low levels of
GATA3 levels in triple-negative breast cancer cases, a majority
of which are likely to correspond to basal-like phenotypes [42].
Differentiation in Breast Cancer Metastasis
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Figure 3.  GATA3 immunohistochemical staining patterns in different types of breast samples and metastases.  (A) The
epithelium of ducts with normal morphology shows predominant GATA3 nuclear staining in the luminal layer. (B and C). GATA3
staining in a primary tumor and its metastasis to lymph node from the same patient than A. Tumor cells are strongly positive for
GATA3 both in the primary (B) and its matched lymph node metastasis (C). (D) Stronger GATA3 staining in infiltrating carcinoma (t)
as compared to its associated ductal carcinoma in situ (dcis). (E) Weak GATA3 staining of a node-negative breast cancer. (F)
Intense GATA3 expression in a lung metastasis of a luminal breast cancer. Most tumor cells show intense positivity.
doi: 10.1371/journal.pone.0078097.g003
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However, we also found that the expression levels of GATA3
and ER were only infrequently diminished in node-positive
primary ductal cancer as compared to node-negative tumors.
Moreover, only about 20% of cases showed a decline in the
expression of these luminal markers in lymph node metastases
as compared to their matched primary tumors, independent of
Figure 4.  Maintenance of GATA3 and ER expression in lymph node metastases of luminal breast cancers.  Samples from
node-negative (PNM) or node-positive (PM) primary tumors, regional lymph node metastases (LNM) and distant metastases (DM)
were immunostained for ER and GATA3, and assigned positive or negative status on the basis of Hscores.
doi: 10.1371/journal.pone.0078097.g004
Figure 5.  Variations in GATA3 and ER expression in node-positive luminal breast tumors and matched lymph node
metastases.  A majority of node-positive luminal-phenotype primary breast cancer cases maintains or increases the expression
levels of ER and GATA3 in their matched lymph node metastases, independent of histological grade. A 20% decrease in Hscores
from PM to its matched LNM was considered a downregulation (DN), a 20% increase an upregulation (UP) and Hscore variations
inferior to 20% were considered as not altered (NA).
doi: 10.1371/journal.pone.0078097.g005
Differentiation in Breast Cancer Metastasis
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Figure 6.  Metastasis-free survival curves for luminal phenotype cases as a function of GATA3 expression status.  (A)
Kaplan-Meier metastasis-free survival actuarial curves for PNM vs. PM cases. (B) Metastasis-free survival actuarial curves
according to GATA3 status. (C) Metastasis-free survival actuarial curves according to molecular phenotype (luminal, HER2(+), TN).
doi: 10.1371/journal.pone.0078097.g006
Differentiation in Breast Cancer Metastasis
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histological grade. In distant metastases, over 70% of HER2(-)
samples expressed ER, GATA3 or both. The latter
observations are in agreement with a recently published report
[43] showing that the majority of breast cancer distant
metastases, including those with luminal and triple-negative
phenotypes in their primary tumors, maintain GATA3
expression. Therefore, our observations suggest that loss of
luminal differentiation may not play a significant role as a driver
of lymph node or distant metastasis in a majority of cases of
luminal breast cancer. In spite of the observed infrequent loss
of luminal differentiation markers in distant metastases, loss of
GATA3 expression in primary tumors with an otherwise luminal
phenotype (positive for ER and/or PR and negative for HER2)
was correlated with a poor metastasis-free survival of patients,
in agreement with previous studies [40,45,46,51].
These observations also raise the question whether GATA3
is a true metastasis suppressor in luminal breast cancer
[37,51,53,54]. Using mouse models, Kouros-Mehr et al. [38]
showed that overexpression of GATA3 in cells from incipient
tumors (adenomas) inhibited their capacity to disseminate after
transplantation, although no evidence was provided as to
whether the establishment of metastasis was enhanced, an
attribute of tumor cells distinct from their capacity to
disseminate. In the same report, conditional knock out of
GATA3 in more advanced tumor cells led to their apoptosis,
indicating that GATA3 was required for the survival of
advanced-stage tumor cells. Moreover, those tumors that
eventually developed reexpressed GATA3. The authors
suggested that such tumors were formed from cells that had
escaped GATA3 knockout [38], suggesting again that those
tumor cells require GATA3 in order to survive.
A putative growth-promoting or maintenance function of
GATA3 might be performed through its transcriptional
repression of the cyclin-dependent kinase inhibitor p18INK4c [55].
In addition, GATA3 appears to promote carcinogenesis in a
lymphoma model induced by the increased expression of c-
Myc [56,57], which in turn induces Notch1 and GATA3 as
putative transcriptional targets that cooperate with Myc to
establish a malignant phenotype [58]. Likewise, GATA3 can be
overexpressed in pancreatic cell lines and primary pancreatic
cancers [41], and in neuroblastoma cell lines [59], where it
positively regulates cyclin D1, maintaining cells in an
undifferentiated state [59], therefore suggesting an oncogenic
potential for GATA3 in neuroblastoma. A further mechanism by
which GATA3 expression might sustain cell growth is through
the positive regulation of the proto-oncogenic aurora-kinase A
in response to estrogen in ER-positive breast cancer cells [60].
Therefore, experimental and correlative evidences suggest a
positive role for GATA3 in the survival and maintenance of the
proliferative state of normal and neoplastic breast epithelial
cells. This, together with our observations and those of Cimino-
Mathews et al. [43] that breast cancer metastases generally
maintain the expression of GATA3, leads us to suggest that
current views of GATA3 as a putative tumor and/or metastasis
suppressor in these tumors merit re-examination.
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